TERT and DNMT1 Expression Predicts Glioma Sensitivity to DAC

TERT and DNMT1 Expression Predicts Glioma Sensitivity to DAC

Original Source Park JW, Sahm F, Steffl B, Arrillaga-Romany I, Cahill D, Monje M, Herold-Mende C, Wick W, Turcan Ş. TERT and DNMT1 expression predict sensitivity to decitabine in gliomas. Neuro Oncol. 2021 Jan 30;23(1):76-87. Research Background Adult diffuse gliomas are mainly classified into three types: isocitrate dehydrogenase (IDH) mutant gliomas with chromosome arm 1p/19q … Read more

Decitabine Combined With Chemotherapy as Second-Line Treatment for R/R DLBCL

Decitabine Combined With Chemotherapy as Second-Line Treatment for R/R DLBCL

Organized by: Oncology Information Source: Oncology Information Recently, a prospective study published by Professor Zhang Mingzhi, Professor Chen Qingjiang, and Professor Zhang Xudong from Zhengzhou University First Affiliated Hospital in Frontiers in Oncology (impact factor 6.244) evaluated the efficacy and safety of decitabine (DAC) combined with cisplatin, cytarabine, and dexamethasone (DHAP) modified regimen in patients … Read more

Introduction to Decitabine (DAC)

Introduction to Decitabine (DAC)

Welcome to reprint, please note the source “Jiangcheng ITP Home”🎉🎉🎉 Decitabine (DAC) is commonly known as an anticancer drug, clinically used for the treatment of myelodysplastic syndromes (MDS), acute myeloid leukemia, chronic myelomonocytic leukemia, and other malignant hematological diseases,because it has demethylation and cytotoxic effects, which can induce cell death. However, its “magical” efficacy in … Read more